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A ‘One Health’ approach identifies the intimate connections between the health of humans, animals 
and our shared environment. The emergence of infectious diseases such as COVID-19 reminds us of 
the importance of identifying and understanding these connections to control and prevent disease. 
Recent data have suggested that SARS-CoV-2 likely originated in horseshoe bats, indicating that 
wider sampling and investigation of animal pathogens could assist the prediction of emerging 
infectious diseases. However, it is equally important to adopt a Comparative Medicine approach, 
recognising and effectively utilising the knowledge of coronavirus biology that has accumulated for 
related veterinary viruses.  Research into animal coronaviruses has led to several successful 
veterinary vaccines, as well as a better understanding of the potential challenges that could inform 
research efforts to develop safe, effective vaccines against SARS-CoV-2. 
 
Animal transmission of infectious disease 
 
The majority of emerging infectious diseases are zoonotic, originating from domesticated animals and 
wildlife1. The COVID-19 pandemic is also a zoonosis, with current evidence suggesting that the human 
virus SARS-CoV-2 is closely related to coronaviruses circulating in bats2. It is therefore important to 
determine whether or not changes in human behaviour are increasing the risk of infectious diseases 
spilling over from wildlife populations into humans. 
 
One factor that affects the risk of emerging infectious diseases is mammalian biodiversity, or the 
number of different species of mammals, in a given area. Where there are many different mammalian 
species in one location, there are also likely to be many different viruses circulating, leading to the 
suggestion that the risk of zoonosis inevitably increases in areas of high biodiversity1. However, the 
link between biodiversity and the risk of emerging zoonotic disease is complex; others argue that 
decreasing biodiversity can also lead to an increased risk. An example of this increased risk, known as 
the dilution effect3, occurs when animals are forced into close proximity as a consequence of loss of 
biodiversity and habitat, resulting in viruses being more easily transmitted from one susceptible host 
to another. 
 
It is widely accepted that the risk of emerging infectious diseases is greatest where human activity 
leads to new interactions with animals and their diseases. For example, habitat change resulting from 
logging and urban expansion decreases biodiversity, but also brings humans into close contact with a 
greater diversity of animals that might be carrying diseases with zoonotic potential. Also, the modern 
global economy encourages travel between large urban centres and remote regions, further 
increasing the risk of severe national and global disease outbreaks. 
 
One method of identifying and managing the risk of emerging infectious diseases is to collect samples 
from animals to identify any diseases that they might be carrying. This is especially relevant to 
coronaviruses; several human and animal diseases, such as severe acute respiratory syndrome (SARS) 
and middle eastern respiratory syndrome (MERS) coronaviruses in humans, and swine acute diarrhoea 
syndrome coronavirus (SADS-CoV) in pigs, are closely related to coronaviruses found in horseshoe 
bats. China has a rich and diverse bat population and a robust surveillance system has been developed 
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that allows the identification of bat coronaviruses. Surveillance studies were used recently to build a 
picture of how coronaviruses evolved in Chinese bat populations, and to identify the key bat species 
and geographical locations driving virus diversity in China4. This study concluded that SARS-CoV-2 is 
likely to have originated in horseshoe bats in Yunnan province, China, a region close to borders with 
Myanmar and Lao PDR, countries that also carry large bat populations. The study also found that the 
stable presence of bats and other mammals in South Western and Southern China over a long 
historical period makes these regions hotspots of coronavirus diversity, as well as areas of high risk 
for the emergence of bat-borne coronaviruses with zoonotic potential. This risk is further amplified as 
the regions are rapidly growing and becoming increasingly urbanised, with more poultry and livestock 
farming bringing bats, domesticated animals and humans into close proximity. A recent study 
indicated that SARS-CoV-2 could have emerged directly from bats. It was postulated that SARS-CoV-2 
did not require significant adaptation to spread amongst humans; this could be an example of a direct 
spillover of a coronavirus into humans5. The ability of the virus to readily infect humans, and other 
mammals, might have arisen as a consequence of ancient evolutionary events as the virus evolved to 
infect different host bat species. It is generally accepted that wider sampling and virus discovery in 
locations with high coronavirus diversity will be necessary to identify viruses with zoonotic potential, 
which could help to prevent future outbreaks. 
 
An additional risk factor for emerging infectious diseases is the illegal animal trade, as well as cultural 
traditions that lead to the consumption of wildlife. These practices can bring humans into close 
contact with animal species that would not normally be encountered, or lead to the hunting of animals 
in areas of high biodiversity. Increased policing of the illegal exotic animal trade could decrease risk, 
as could changing the way in which wild animals are captured or hunted for meat. If farming methods 
for such animals can be introduced and regulated in a way that increases biosecurity (broadly, the 
control of infections entering or exiting a farm), then it might be possible to minimise the risk of 
emerging diseases whilst also respecting cultural traditions.  
 
Have vaccines been developed for animal coronaviruses? 
 
Coronaviruses infect a wide variety of mammals and birds and are commonly associated with enteric 
and respiratory illnesses. Effective veterinary coronavirus vaccines have been developed against 
several animal coronaviruses that cause economically and clinically important diseases of domestic 
animals, such as pigs, chickens, dogs and cats. However, some of these vaccines have only short-term 
efficacy because of the emergence of new virus variants. Coronaviruses are divided into four groups - 
alpha, beta, delta, and gamma, and vaccines have been developed against coronaviruses belonging to 
each of these groups.   Veterinary coronavirus vaccines that are commercially available in the UK 
include vaccines against infectious bronchitis virus infection in poultry (gammacoronavirus), canine 
enteric coronavirus infection in dogs (alphacoronavirus), porcine epidemic diarrhoea virus and 
transmissible gastroenteritis virus (alphacoronavirus) infection in pigs, and bovine coronavirus virus 
(betacoronavirus) infection that causes shipping fever in young calves. 
  
It might be significant that the majority of licensed veterinary vaccines have been developed to protect 
against alphacoronaviruses, whereas the COVID-19 virus is a betacoronavirus. It will be important to 
establish what knowledge gained from the development of these vaccines is applicable to 
betacoronaviruses, and to recognise that the development of a COVID-19 vaccine may present 
unforeseen hurdles and challenges. It is notable that many attempts have been made to develop feline 
coronavirus (FCoV) vaccines, most of which failed. Understanding why some experimental vaccines 
failed to protect cats from FCoV infection could have comparative value, informing the development 




The challenges of developing a feline coronavirus vaccine 
 
Feline coronavirus infects domestic, feral and some wild cats. Most cats infected with feline 
coronavirus remain healthy or develop only mild enteritis.  However, a small proportion will develop 
feline infectious peritonitis (FIP), a disease with a very poor prognosis; many cats that develop FIP die 
or are euthanised. The virulence of the virus, the viral load and the cat’s immune response are factors 
that determine whether or not FIP will develop. The role of antibodies in preventing cats from 
developing feline infectious peritonitis is unclear6.  
 
In experimental studies, it was found that some FCoV vaccine candidates induced antibodies that 
neutralised the virus while others bound to the virus and increased viral uptake; this phenomenon, 
known as antibody-dependent enhancement of infection7, apparently amplified rather than 
prevented disease8. Although cats that developed antibodies following vaccination were more likely 
than unvaccinated cats to develop FIP after being experimentally infected with the virus9, antibody-
positive cats that had been naturally exposed to virus did not show enhanced disease10. This difference 
could have been related to the higher doses of virus to which cats were exposed in experimental 
infections compared to natural infections. Alternatively, the difference could be related to the virus 
being administered experimentally by injection whereas, in natural field infections, cats are exposed 
to the virus at mucosal surfaces10. 
 
Currently there is one intranasal FCoV vaccine that is available commercially in the USA and in some 
European countries. The vaccine is administered intranasally and contains an attenuated virus that 
replicates efficiently at mucosal surfaces in the upper respiratory tract but cannot replicate at the 
higher temperatures within the lower respiratory tract. The attenuated virus stimulates an effective 
immune response that does not lead to antibody-dependent enhancement and avoids the risk of 
severe disease caused by virus replication in the lower respiratory tract. The vaccine is not 
recommended for use in antibody-positive cats, since such cats will either have natural immunity, or 
will already be incubating FIP11. However, intranasal vaccination of antibody-negative kittens has been 
shown to be safe and effective11. 
 
How could a One Health approach prevent emerging infections?  
 
There are no simple solutions for preventing emerging disease outbreaks, but it might be possible to 
predict the likelihood of the emergence of new infections such as SARS-CoV-2 using surveillance 
systems to identify viruses circulating in wild and domestic animals. Ideally, surveillance would be 
combined with the restoration of animal habitats, encouraging animals to forage in areas free from 
human interference. Community engagement and government policies could also be implemented to 
control human behaviours that increase the risk of human exposure to animal pathogens. It might also 
be possible to mitigate the risk of emerging infections through research and the development of 
vaccines and other disease control strategies for wild and domestic animal populations, which 
ultimately would also lead to improvements in human health. This is most likely to be achieved by 
taking a broad approach to One Health that encompasses Comparative Medicine to have the greatest 
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The emergence of COVID-19 illustrates the intimate connections between the health of humans, 
animals and our shared environment and highlights the importance of a One Health approach, which 
encourages integration between multiple sectors and disciplines to improved public, animal and 
environmental health. Comparative Medicine complements a One Health approach, having an 
important role in the prevention and control of emerging infectious diseases such as COVID-19 by 
contributing to an improved understanding of coronavirus biology, the pathogenesis of coronavirus 
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